These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 25023760)

  • 1. Systemic vascular safety of ranibizumab for age-related macular degeneration: systematic review and meta-analysis of randomized trials.
    Ueta T; Noda Y; Toyama T; Yamaguchi T; Amano S
    Ophthalmology; 2014 Nov; 121(11):2193-203.e1-7. PubMed ID: 25023760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis.
    Thulliez M; Angoulvant D; Le Lez ML; Jonville-Bera AP; Pisella PJ; Gueyffier F; Bejan-Angoulvant T
    JAMA Ophthalmol; 2014 Nov; 132(11):1317-26. PubMed ID: 25058694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration.
    Moja L; Lucenteforte E; Kwag KH; Bertele V; Campomori A; Chakravarthy U; D'Amico R; Dickersin K; Kodjikian L; Lindsley K; Loke Y; Maguire M; Martin DF; Mugelli A; Mühlbauer B; Püntmann I; Reeves B; Rogers C; Schmucker C; Subramanian ML; Virgili G
    Cochrane Database Syst Rev; 2014 Sep; 9(9):CD011230. PubMed ID: 25220133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic Safety of Prolonged Monthly Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema: A Systematic Review and Meta-analysis.
    Avery RL; Gordon GM
    JAMA Ophthalmol; 2016 Jan; 134(1):21-9. PubMed ID: 26513684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.
    Busbee BG; Ho AC; Brown DM; Heier JS; Suñer IJ; Li Z; Rubio RG; Lai P;
    Ophthalmology; 2013 May; 120(5):1046-56. PubMed ID: 23352196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic safety of ranibizumab for diabetic macular edema: meta-analysis of randomized trials.
    Yanagida Y; Ueta T
    Retina; 2014 Apr; 34(4):629-35. PubMed ID: 24667549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implications of the comparisons of age-related macular degeneration treatments trials on clinical practice: what have we learned?
    Do DV
    Ophthalmology; 2013 May; 120(5 Suppl):S8-10. PubMed ID: 23642785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and adverse events of aflibercept, ranibizumab and bevacizumab in age-related macular degeneration: a trade-off analysis.
    Schmid MK; Bachmann LM; Fäs L; Kessels AG; Job OM; Thiel MA
    Br J Ophthalmol; 2015 Feb; 99(2):141-6. PubMed ID: 25271911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.
    Ho AC; Busbee BG; Regillo CD; Wieland MR; Van Everen SA; Li Z; Rubio RG; Lai P;
    Ophthalmology; 2014 Nov; 121(11):2181-92. PubMed ID: 25015215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials.
    Bressler NM; Boyer DS; Williams DF; Butler S; Francom SF; Brown B; Di Nucci F; Cramm T; Tuomi LL; Ianchulev T; Rubio RG
    Retina; 2012 Oct; 32(9):1821-8. PubMed ID: 23011184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overview of Systematic Reviews and Meta-analyses on Systemic Adverse Events Associated With Intravitreal Anti-Vascular Endothelial Growth Factor Medication Use.
    Thulliez M; Angoulvant D; Pisella PJ; Bejan-Angoulvant T
    JAMA Ophthalmol; 2018 May; 136(5):557-566. PubMed ID: 29566105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ranibizumab for age-related macular degeneration: a meta-analysis of dose effects and comparison with no anti-VEGF treatment and bevacizumab.
    Jiang S; Park C; Barner JC
    J Clin Pharm Ther; 2014 Jun; 39(3):234-9. PubMed ID: 24635444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ranibizumab injection for diabetic macular edema: meta-analysis of systemic safety and systematic review.
    Abouammoh MA
    Can J Ophthalmol; 2013 Aug; 48(4):317-23. PubMed ID: 23931473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab versus ranibizumab for neovascular age-related macular degeneration: a meta-analysis of randomized controlled trials.
    Chen G; Li W; Tzekov R; Jiang F; Mao S; Tong Y
    Retina; 2015 Feb; 35(2):187-93. PubMed ID: 25105318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravitreal anti-vascular endothelial growth factor treatment and the risk of thromboembolism.
    Schlenker MB; Thiruchelvam D; Redelmeier DA
    Am J Ophthalmol; 2015 Sep; 160(3):569-580.e5. PubMed ID: 26116264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravitreal Bevacizumab and Cardiovascular Risk in Patients with Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Randomized Controlled Trials and Observational Studies.
    Mikačić I; Bosnar D
    Drug Saf; 2016 Jun; 39(6):517-41. PubMed ID: 26951234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab.
    Mitchell P
    Curr Med Res Opin; 2011 Jul; 27(7):1465-75. PubMed ID: 21623685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study results.
    Larsen M; Schmidt-Erfurth U; Lanzetta P; Wolf S; Simader C; Tokaji E; Pilz S; Weisberger A;
    Ophthalmology; 2012 May; 119(5):992-1000. PubMed ID: 22424834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol.
    Berg K; Pedersen TR; Sandvik L; Bragadóttir R
    Ophthalmology; 2015 Jan; 122(1):146-52. PubMed ID: 25227499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.
    Kodjikian L; Souied EH; Mimoun G; Mauget-Faÿsse M; Behar-Cohen F; Decullier E; Huot L; Aulagner G;
    Ophthalmology; 2013 Nov; 120(11):2300-9. PubMed ID: 23916488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.